Navin Fluorine International Announces Key Leadership Changes in CDMO Business
Navin Fluorine International Limited has announced key leadership changes in its CDMO Business division. Mr. Rajendra Sahu, the current CEO, will step down on September 20, 2025. Dr. Vijay Kaiwar has been appointed as the new CEO Designate, taking full responsibilities from September 21, 2025. Dr. Kaiwar brings nearly 30 years of experience in CDMO and API businesses, with expertise in various functions and technologies. He holds a Ph.D. in Organic Chemistry and has held senior roles at several renowned pharmaceutical companies.

*this image is generated using AI for illustrative purposes only.
Navin Fluorine International Limited , a prominent player in the fluorochemicals industry, has announced significant leadership changes in its Contract Development and Manufacturing Organization (CDMO) Business division, signaling a new chapter for the company's strategic growth.
Departure of Current CEO
Mr. Rajendra Sahu, the current CEO of the CDMO Business, has tendered his resignation to pursue career opportunities elsewhere. His tenure with Navin Fluorine International will conclude on September 20, 2025, marking the end of his leadership in this crucial division.
Appointment of New CEO
In a strategic move to ensure a smooth transition and continued growth, Navin Fluorine International has appointed Dr. Vijay Kaiwar as the CEO Designate of the CDMO Business. Dr. Kaiwar will assume full CEO responsibilities effective September 21, 2025, bringing with him a wealth of experience and expertise to the role.
Dr. Vijay Kaiwar's Profile
Dr. Kaiwar joins Navin Fluorine International with an impressive background:
- Nearly 30 years of experience in CDMO and API businesses
- Specialization in Chemistry and Biotechnology
- Leadership exposure across multiple functions, including R&D, Technology Transfer, Operations, Projects, Manufacturing, EHS, and Business Development
- Senior leadership roles at renowned companies such as Anthem Biosciences, Sun Pharma, Aurobindo Pharma, Jubilant Organosys, and Atul Limited
- Strong partnerships with leading global pharmaceutical and biotech companies
- Expertise in regulatory affairs and a broad spectrum of technologies
Educational Background
Dr. Kaiwar's academic credentials further underscore his expertise in the field:
- Ph.D. in Organic Chemistry from IICT Hyderabad
- Post-Doctoral Fellowship from King's College, London
Impact on Navin Fluorine International
The appointment of Dr. Kaiwar is expected to bring fresh perspectives and deep industry knowledge to Navin Fluorine International's CDMO Business. His extensive experience in building partnerships with global pharmaceutical clients and expertise in various advanced technologies aligns well with the company's focus on innovation and growth in the CDMO sector.
This leadership transition comes at a time when the CDMO industry is experiencing significant growth and transformation. Dr. Kaiwar's diverse skill set and experience in managing high-performing teams are likely to be valuable assets as Navin Fluorine International seeks to strengthen its position in the global CDMO market.
The company's proactive approach in announcing these changes well in advance demonstrates its commitment to ensuring a smooth transition and maintaining stakeholder confidence. As Navin Fluorine International embarks on this new phase under Dr. Kaiwar's leadership, the industry will be watching closely to see how these changes shape the company's future trajectory in the competitive CDMO landscape.
Historical Stock Returns for Navin Fluorine International
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
-4.06% | -4.66% | -6.01% | +27.09% | +45.09% | +124.62% |